Rafael Salguero-Bodes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rafael Salguero-Bodes has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Arribas
Hospital Universitario 12 de Octubre
26 shared publications Fernando Arribas-Ynsaurriaga
25 shared publications- María López-Gil
Unidad de Arritmias, Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain
19 shared publications - Adolfo Fontenla
Cardiology Department, Hospital Universitario Quironsalud Madrid, Madrid, Spain; Department of Medicine, Faculty of Medicine, Health and Sports, Universidad Europea de Madrid, Madrid, Spain
15 shared publications Fernando Arribas Ynsaurriaga
Department of Cardiology, Hospital Universitario 12 de Octubre. Instituto de Investigación Sanitaria Hospital, CIBERCV, Madrid, Spain
13 shared publicationsC. Senz de la Calzada Campos
Servicio de Cardiología. Hospital 12 de Octubre. Madrid
11 shared publications
Latest Publications
- Open Access
- 25 October 2026
- Published by Elsevier in SSRN Electronic Journal
Beyond the Mode of Death: Clinical End-of-Life Trajectories in the Cardiac Intensive Care Unit
BackgroundDeath in the contemporary cardiac intensive care unit (CICU) is heterogeneous but often described according to treatment-limitation decisions or immediate causes of death rather than integrated clinical pathways. We sought to characterize distinct end-of-life trajectories and examine differences in baseline vulnerability, acute illness severity, therapeutic intensity, decision-making, and causes of death.MethodsWe conducted a retrospective observational cohort study of 200 consecutive adults who died during admission to a tertiary CICU between 2024 and 2025. Using prespecified operational criteria, patients were classified into five mutually exclusive trajectories: refractory death, failure-to-recover, non-escalation, withdrawal after advanced support, and early limitation. Clinical characteristics, organ support, treatment-limitation practices, and immediate causes of death were compared across trajectories.ResultsFive trajectories were identified: refractory death (11.0%), failure-to-recover (11.5%), non-escalation (38.5%), withdrawal after advanced support (1.5%), and early limitation (37.5%). Non-escalation and early limitation together accounted for 76.0% of deaths. Refractory death occurred predominantly in younger, less frail patients with greater acute physiological derangement and higher therapeutic intensity. The median therapeutic intensity score was 3 (IQR 3–4) in refractory death versus 1 (IQR 1–2) in non-escalation. Baseline vulnerability, treatment intensity, timing and reasons for treatment limitation, organ support, and immediate causes of death differed across trajectories.ConclusionsPatients dying in the contemporary CICU follow heterogeneous end-of-life trajectories shaped by baseline vulnerability, acute illness severity, therapeutic intensity, and evolving goals of care. This trajectory-based framework complements classifications based on immediate cause of death or individual treatment-limitation decisions.
- 25 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBeyond the Mode of Death: Clinical End-of-Life Trajectories in the Cardiac Intensive Care Unit
BackgroundDeath in the contemporary cardiac intensive care unit (CICU) is heterogeneous but often described according to treatment-limitation decisions or immediate causes of death rather than integrated clinical pathways. We sought to characterize distinct end-of-life trajectories and examine differences in baseline vulnerability, acute illness severity, therapeutic intensity, decision-making, and causes of death.MethodsWe conducted a retrospective observational cohort study of 200 consecutive adults who died during admission to a tertiary CICU between 2024 and 2025. Using prespecified operational criteria, patients were classified into five mutually exclusive trajectories: refractory death, failure-to-recover, non-escalation, withdrawal after advanced support, and early limitation. Clinical characteristics, organ support, treatment-limitation practices, and immediate causes of death were compared across trajectories.ResultsFive trajectories were identified: refractory death (11.0%), failure-to-recover (11.5%), non-escalation (38.5%), withdrawal after advanced support (1.5%), and early limitation (37.5%). Non-escalation and early limitation together accounted for 76.0% of deaths. Refractory death occurred predominantly in younger, less frail patients with greater acute physiological derangement and higher therapeutic intensity. The median therapeutic intensity score was 3 (IQR 3–4) in refractory death versus 1 (IQR 1–2) in non-escalation. Baseline vulnerability, treatment intensity, timing and reasons for treatment limitation, organ support, and immediate causes of death differed across trajectories.ConclusionsPatients dying in the contemporary CICU follow heterogeneous end-of-life trajectories shaped by baseline vulnerability, acute illness severity, therapeutic intensity, and evolving goals of care. This trajectory-based framework complements classifications based on immediate cause of death or individual treatment-limitation decisions.
- Open Access
- 18 September 2026
- Published by Elsevier in SSRN Electronic Journal
Beyond the Mode of Death: Clinical End-of-Life Trajectories in the Cardiac Intensive Care Unit
BackgroundDeath in the contemporary cardiac intensive care unit (CICU) is heterogeneous but often described according to treatment-limitation decisions or immediate causes of death rather than integrated clinical pathways. We sought to characterize distinct end-of-life trajectories and examine differences in baseline vulnerability, acute illness severity, therapeutic intensity, decision-making, and causes of death.MethodsWe conducted a retrospective observational cohort study of 200 consecutive adults who died during admission to a tertiary CICU between 2024 and 2025. Using prespecified operational criteria, patients were classified into five mutually exclusive trajectories: refractory death, failure-to-recover, non-escalation, withdrawal after advanced support, and early limitation. Clinical characteristics, organ support, treatment-limitation practices, and immediate causes of death were compared across trajectories.ResultsFive trajectories were identified: refractory death (11.0%), failure-to-recover (11.5%), non-escalation (38.5%), withdrawal after advanced support (1.5%), and early limitation (37.5%). Non-escalation and early limitation together accounted for 76.0% of deaths. Refractory death occurred predominantly in younger, less frail patients with greater acute physiological derangement and higher therapeutic intensity. The median therapeutic intensity score was 3 (IQR 3–4) in refractory death versus 1 (IQR 1–2) in non-escalation. Baseline vulnerability, treatment intensity, timing and reasons for treatment limitation, organ support, and immediate causes of death differed across trajectories.ConclusionsPatients dying in the contemporary CICU follow heterogeneous end-of-life trajectories shaped by baseline vulnerability, acute illness severity, therapeutic intensity, and evolving goals of care. This trajectory-based framework complements classifications based on immediate cause of death or individual treatment-limitation decisions.
- 18 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBeyond the Mode of Death: Clinical End-of-Life Trajectories in the Cardiac Intensive Care Unit
BackgroundDeath in the contemporary cardiac intensive care unit (CICU) is heterogeneous but often described according to treatment-limitation decisions or immediate causes of death rather than integrated clinical pathways. We sought to characterize distinct end-of-life trajectories and examine differences in baseline vulnerability, acute illness severity, therapeutic intensity, decision-making, and causes of death.MethodsWe conducted a retrospective observational cohort study of 200 consecutive adults who died during admission to a tertiary CICU between 2024 and 2025. Using prespecified operational criteria, patients were classified into five mutually exclusive trajectories: refractory death, failure-to-recover, non-escalation, withdrawal after advanced support, and early limitation. Clinical characteristics, organ support, treatment-limitation practices, and immediate causes of death were compared across trajectories.ResultsFive trajectories were identified: refractory death (11.0%), failure-to-recover (11.5%), non-escalation (38.5%), withdrawal after advanced support (1.5%), and early limitation (37.5%). Non-escalation and early limitation together accounted for 76.0% of deaths. Refractory death occurred predominantly in younger, less frail patients with greater acute physiological derangement and higher therapeutic intensity. The median therapeutic intensity score was 3 (IQR 3–4) in refractory death versus 1 (IQR 1–2) in non-escalation. Baseline vulnerability, treatment intensity, timing and reasons for treatment limitation, organ support, and immediate causes of death differed across trajectories.ConclusionsPatients dying in the contemporary CICU follow heterogeneous end-of-life trajectories shaped by baseline vulnerability, acute illness severity, therapeutic intensity, and evolving goals of care. This trajectory-based framework complements classifications based on immediate cause of death or individual treatment-limitation decisions.
- Open Access
- 5 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6885
Operational Ethics in the Cardiovascular Intensive Care Unit: A Practical Framework for Ethical Decision-Making
Background/Objectives: Contemporary cardiovascular critical care is increasingly shaped by advanced technologies, prognostic uncertainty, and time-sensitive decisions regarding mechanical circulatory support, treatment limitation, device management, family communication, and end-of-life care. Although established ethical principles provide essential normative guidance, their integration into routine bedside workflows remains challenging. This review examines the principal ethical tensions arising in the Cardiovascular Intensive Care Unit (CICU) and proposes a practical framework for real-time ethical decision-making. Methods: A narrative review of the contemporary literature was performed using major biomedical databases together with international guidelines, scientific statements, consensus documents, and relevant ethics literature to identify the principal ethical challenges encountered in contemporary cardiovascular intensive care and to develop an implementation-oriented framework for integrating ethical reasoning into routine clinical workflows. Results: Ethical challenges in the CICU frequently arise during transitions between therapeutic escalation, reassessment, limitation, withdrawal, and comfort-focused care. These decisions are influenced not only by clinical prognosis but also by organisational culture, multidisciplinary dynamics, patient preferences, communication, and structural inequities. We propose Operational Ethics as an implementation framework that embeds ethical reflection into routine clinical workflows through continuous reassessment of therapeutic goals, proportionality, prognosis, patient values, and multidisciplinary deliberation. Practical strategies include ethical pause points, time-limited trials, structured communication pathways, anticipatory device discussions, regular goals-of-care reassessment, and institutional support for clinicians experiencing moral distress. Conclusions: Operational Ethics complements established bioethical principles by translating them into practical bedside processes adapted to the temporal and organisational realities of cardiovascular critical care. Its integration into routine CICU practice may support more consistent, equitable, and patient-centred decisions while ensuring that technological possibilities remain aligned with meaningful clinical goals.
- 5 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6885
Open AccessOperational Ethics in the Cardiovascular Intensive Care Unit: A Practical Framework for Ethical Decision-Making
Background/Objectives: Contemporary cardiovascular critical care is increasingly shaped by advanced technologies, prognostic uncertainty, and time-sensitive decisions regarding mechanical circulatory support, treatment limitation, device management, family communication, and end-of-life care. Although established ethical principles provide essential normative guidance, their integration into routine bedside workflows remains challenging. This review examines the principal ethical tensions arising in the Cardiovascular Intensive Care Unit (CICU) and proposes a practical framework for real-time ethical decision-making. Methods: A narrative review of the contemporary literature was performed using major biomedical databases together with international guidelines, scientific statements, consensus documents, and relevant ethics literature to identify the principal ethical challenges encountered in contemporary cardiovascular intensive care and to develop an implementation-oriented framework for integrating ethical reasoning into routine clinical workflows. Results: Ethical challenges in the CICU frequently arise during transitions between therapeutic escalation, reassessment, limitation, withdrawal, and comfort-focused care. These decisions are influenced not only by clinical prognosis but also by organisational culture, multidisciplinary dynamics, patient preferences, communication, and structural inequities. We propose Operational Ethics as an implementation framework that embeds ethical reflection into routine clinical workflows through continuous reassessment of therapeutic goals, proportionality, prognosis, patient values, and multidisciplinary deliberation. Practical strategies include ethical pause points, time-limited trials, structured communication pathways, anticipatory device discussions, regular goals-of-care reassessment, and institutional support for clinicians experiencing moral distress. Conclusions: Operational Ethics complements established bioethical principles by translating them into practical bedside processes adapted to the temporal and organisational realities of cardiovascular critical care. Its integration into routine CICU practice may support more consistent, equitable, and patient-centred decisions while ensuring that technological possibilities remain aligned with meaningful clinical goals.
- Open Access
- 2 September 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (9)
Pulmonary vein isolation durability in a randomized trial comparing fluoroscopy-only vs. electroanatomic mapping strategies for pulmonary vein isolation with balloon-in-basket pulsed-field ablation
Aims: Data on long-term durability of pulmonary vein isolation (PVI) with newer pulsed field ablation (PFA) platforms and incremental value of electroanatomic mapping (EAM) guidance remain limited. This study evaluated chronic PVI durability following ablation with a balloon-in-basket PFA catheter and compared outcomes of fluoroscopy-only vs. fluoroscopy plus EAM workflows. Methods and results: In this prospective, single-centre trial, consecutive patients with paroxysmal or persistent atrial fibrillation (AF) underwent de novo PVI with a balloon-in-basket PFA catheter. Patients were randomized 1:1 to fluoroscopy-only or fluoroscopy plus EAM workflow. Systematic invasive remapping was planned >30 days after the index procedure. The dual primary efficacy endpoint was the proportion of pulmonary veins (PVs) and of patients with all PVs durably isolated. The prespecified secondary endpoint was the comparison of procedural characteristics and PVI durability between workflows. Safety outcomes included major adverse events within 30 days of index or remapping procedures. Ninety-six patients (67.4 ± 9.2 years, 44.8% female, 57.3% with paroxysmal AF) underwent index ablation. Fluoroscopy time and number of applications were 3.4 [2.4–4.6] minutes and 15 [13–16], respectively. Systematic remapping was performed in 86 patients at a median of 41 days, with per-vein and per-patient durability of 341/350 (97.4%), and 79/86 (91.9%) respectively. PVI durability and chronic remapping parameters were comparable between guidance strategies. No major adverse events occurred. Conclusion: A standardized balloon-in-basket PFA workflow for PVI achieved high PVI durability. EAM guidance did not confer additional procedural or durability benefit over fluoroscopy-only guidance.
- 2 September 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (9)
Open AccessPulmonary vein isolation durability in a randomized trial comparing fluoroscopy-only vs. electroanatomic mapping strategies for pulmonary vein isolation with balloon-in-basket pulsed-field ablation
Aims: Data on long-term durability of pulmonary vein isolation (PVI) with newer pulsed field ablation (PFA) platforms and incremental value of electroanatomic mapping (EAM) guidance remain limited. This study evaluated chronic PVI durability following ablation with a balloon-in-basket PFA catheter and compared outcomes of fluoroscopy-only vs. fluoroscopy plus EAM workflows. Methods and results: In this prospective, single-centre trial, consecutive patients with paroxysmal or persistent atrial fibrillation (AF) underwent de novo PVI with a balloon-in-basket PFA catheter. Patients were randomized 1:1 to fluoroscopy-only or fluoroscopy plus EAM workflow. Systematic invasive remapping was planned >30 days after the index procedure. The dual primary efficacy endpoint was the proportion of pulmonary veins (PVs) and of patients with all PVs durably isolated. The prespecified secondary endpoint was the comparison of procedural characteristics and PVI durability between workflows. Safety outcomes included major adverse events within 30 days of index or remapping procedures. Ninety-six patients (67.4 ± 9.2 years, 44.8% female, 57.3% with paroxysmal AF) underwent index ablation. Fluoroscopy time and number of applications were 3.4 [2.4–4.6] minutes and 15 [13–16], respectively. Systematic remapping was performed in 86 patients at a median of 41 days, with per-vein and per-patient durability of 341/350 (97.4%), and 79/86 (91.9%) respectively. PVI durability and chronic remapping parameters were comparable between guidance strategies. No major adverse events occurred. Conclusion: A standardized balloon-in-basket PFA workflow for PVI achieved high PVI durability. EAM guidance did not confer additional procedural or durability benefit over fluoroscopy-only guidance.
- Open Access
- 17 August 2026
- Published by MDPI AG in Geriatrics
- Vol. 11 (4) , 106
Beyond Chronological Age: Frailty, Vulnerability, and Invasive Decision-Making in Older Adults with Acute Coronary Syndromes
Older adults represent a growing proportion of patients presenting with acute coronary syndromes (ACS), yet they remain a highly heterogeneous population in terms of biological reserve, comorbidity burden, functional status, cognitive performance, and recovery potential. Chronological age alone is an insufficient basis for invasive decision-making, as it may lead to both therapeutic nihilism and disproportionate treatment escalation. Frailty has emerged as a clinically meaningful construct that captures vulnerability to acute stressors and may refine prognostic assessment beyond traditional cardiovascular risk scores. In ACS, frailty is associated with mortality, bleeding, procedural complications, delirium, functional decline, readmission, and loss of independence. However, frailty should not be interpreted as an automatic contraindication to invasive management. Rather, it should inform proportional care by integrating ischemic risk, procedural burden, reversibility potential, patient preferences, and expected quality of recovery. This narrative review examines the role of frailty assessment in older adults with ACS, focusing on its implications for invasive decision-making. We discuss frailty tools, clinical outcomes, therapeutic bias, healthcare inequities, and patient-centered endpoints. Finally, we propose a vulnerability-based framework for cardiovascular care, in which frailty guides individualized therapeutic intensity rather than justifying age-based exclusion from evidence-based treatment.
- 17 August 2026
- Published by MDPI AG in Geriatrics
- Vol. 11 (4) , 106
Open AccessBeyond Chronological Age: Frailty, Vulnerability, and Invasive Decision-Making in Older Adults with Acute Coronary Syndromes
Older adults represent a growing proportion of patients presenting with acute coronary syndromes (ACS), yet they remain a highly heterogeneous population in terms of biological reserve, comorbidity burden, functional status, cognitive performance, and recovery potential. Chronological age alone is an insufficient basis for invasive decision-making, as it may lead to both therapeutic nihilism and disproportionate treatment escalation. Frailty has emerged as a clinically meaningful construct that captures vulnerability to acute stressors and may refine prognostic assessment beyond traditional cardiovascular risk scores. In ACS, frailty is associated with mortality, bleeding, procedural complications, delirium, functional decline, readmission, and loss of independence. However, frailty should not be interpreted as an automatic contraindication to invasive management. Rather, it should inform proportional care by integrating ischemic risk, procedural burden, reversibility potential, patient preferences, and expected quality of recovery. This narrative review examines the role of frailty assessment in older adults with ACS, focusing on its implications for invasive decision-making. We discuss frailty tools, clinical outcomes, therapeutic bias, healthcare inequities, and patient-centered endpoints. Finally, we propose a vulnerability-based framework for cardiovascular care, in which frailty guides individualized therapeutic intensity rather than justifying age-based exclusion from evidence-based treatment.
- Open Access
- 4 August 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (5) , 440-453
Left Ventricular Hypertrabeculation and Prognosis in Dilated Cardiomyopathy
BACKGROUND: Left ventricular (LV) hypertrabeculation, formerly termed LV noncompaction, is a heterogeneous myocardial entity linked to adverse cardiovascular outcomes. This study evaluated embolic risk in patients with dilated cardiomyopathy (DCM) according to the presence of hypertrabeculation and examined its prevalence and prognostic relevance across DCM genotypes. METHODS: Clinical data from 1160 patients with DCM evaluated by cardiac magnetic resonance imaging and genetic testing (n=997 [86%]) were collected from 22 international centers. End points included embolic events, advanced heart failure events, and major ventricular arrhythmias. RESULTS: LV hypertrabeculation was identified in 354 patients (30.5%) by fractal analysis and in 343 (29.7%) according to Petersen criteria, with good concordance. After a median follow-up of 5.1 years (interquartile range, 2.8–7.4), embolic events occurred in 37 patients (3.2%), advanced heart failure in 62 (5.3%), and major ventricular arrhythmias in 136 (11.7%). Hypertrabeculation was not associated with increased embolic risk (hazard ratio, 1.5 [95% CI, 0.75–3.00]), even among patients in sinus rhythm with LV ejection fraction ≤40% (hazard ratio, 1.89 [95% CI, 0.7–5.5]). In contrast, atrial fibrillation and reduced LV ejection fraction were associated with embolic events (both P TTN (38%), and genotype-negative status (33%), and the lowest prevalence observed among those with variants in cytoskeletal/Z-disk (7%) and nuclear envelope (5%) genes. Hypertrabeculation was not associated with adverse outcomes within any genotype. CONCLUSIONS: Although LV hypertrabeculation is common in DCM, it is not associated with worse outcomes and should not prompt differential clinical management. The embolic risk in patients with DCM and hypertrabeculation is low, including in those with reduced LV ejection fraction without atrial fibrillation, and does not support prophylactic anticoagulation in these patients.
- 4 August 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (5) , 440-453
Open AccessLeft Ventricular Hypertrabeculation and Prognosis in Dilated Cardiomyopathy
BACKGROUND: Left ventricular (LV) hypertrabeculation, formerly termed LV noncompaction, is a heterogeneous myocardial entity linked to adverse cardiovascular outcomes. This study evaluated embolic risk in patients with dilated cardiomyopathy (DCM) according to the presence of hypertrabeculation and examined its prevalence and prognostic relevance across DCM genotypes. METHODS: Clinical data from 1160 patients with DCM evaluated by cardiac magnetic resonance imaging and genetic testing (n=997 [86%]) were collected from 22 international centers. End points included embolic events, advanced heart failure events, and major ventricular arrhythmias. RESULTS: LV hypertrabeculation was identified in 354 patients (30.5%) by fractal analysis and in 343 (29.7%) according to Petersen criteria, with good concordance. After a median follow-up of 5.1 years (interquartile range, 2.8–7.4), embolic events occurred in 37 patients (3.2%), advanced heart failure in 62 (5.3%), and major ventricular arrhythmias in 136 (11.7%). Hypertrabeculation was not associated with increased embolic risk (hazard ratio, 1.5 [95% CI, 0.75–3.00]), even among patients in sinus rhythm with LV ejection fraction ≤40% (hazard ratio, 1.89 [95% CI, 0.7–5.5]). In contrast, atrial fibrillation and reduced LV ejection fraction were associated with embolic events (both P TTN (38%), and genotype-negative status (33%), and the lowest prevalence observed among those with variants in cytoskeletal/Z-disk (7%) and nuclear envelope (5%) genes. Hypertrabeculation was not associated with adverse outcomes within any genotype. CONCLUSIONS: Although LV hypertrabeculation is common in DCM, it is not associated with worse outcomes and should not prompt differential clinical management. The embolic risk in patients with DCM and hypertrabeculation is low, including in those with reduced LV ejection fraction without atrial fibrillation, and does not support prophylactic anticoagulation in these patients.
- 28 May 2026
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 69 (7) , 2085-2095
Substrate ablation as concomitant treatment for left atrial macroreentrant tachycardia (SLICE-LAMRT): rationale and study design
Left atrial macroreentrant tachycardias (LAMRTs) are increasing, particularly following atrial fibrillation ablation. Conventional ablation strategies based on activation mapping are limited by the presence of multiple inducible circuits and high recurrence rates. The potential benefit of a substrate-guided approach targeting reproducible anatomical reentry pathways remains unknown. We hypothesize that a substrate-guided approach, targeting reproducible anatomical pathways sustaining reentry rather than only inducible tachycardias, will improve rhythm control and clinical outcomes compared with conventional ablation strategies. The goal of this trial is to determine whether substrate-guided catheter ablation is superior to activation-guided ablation in reducing atrial arrhythmia recurrence in patients with LAMRT. The SLICE-LAMRT trial is an investigator-initiated, prospective, multicenter, randomized (1:1) study conducted at 12 centers in Spain. Patients and clinical event adjudicators are blinded to treatment allocation. Patients with LAMRT and significant left atrial low-voltage substrate are randomized to either a conventional activation-guided ablation strategy, based on high-density mapping and entrainment pacing of clinical and inducible tachycardias, or a substrate-guided approach consisting of a predefined left atrial ablation line set. This study has been registered at ClinicalTrials.gov (NCT05842499). The primary endpoint is atrial tachyarrhythmia recurrence and time to first recurrence after a 3-month blanking period. Secondary endpoints include procedural performance, acute efficacy, major clinical outcomes (including hospitalizations and mortality), and echocardiographic parameters. Safety endpoints include procedure-related adverse events such as death, stroke, cardiac tamponade, vascular complications, and other major complications. The SLICE-LAMRT trial will provide the first randomized evidence comparing substrate-guided and activation-guided ablation strategies in LAMRT. By addressing a major unmet clinical need, this study may inform and refine ablation strategies for atypical atrial flutter and support a shift toward substrate-based approaches in complex atrial arrhythmias.
- 28 May 2026
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 69 (7) , 2085-2095
Substrate ablation as concomitant treatment for left atrial macroreentrant tachycardia (SLICE-LAMRT): rationale and study design
Left atrial macroreentrant tachycardias (LAMRTs) are increasing, particularly following atrial fibrillation ablation. Conventional ablation strategies based on activation mapping are limited by the presence of multiple inducible circuits and high recurrence rates. The potential benefit of a substrate-guided approach targeting reproducible anatomical reentry pathways remains unknown. We hypothesize that a substrate-guided approach, targeting reproducible anatomical pathways sustaining reentry rather than only inducible tachycardias, will improve rhythm control and clinical outcomes compared with conventional ablation strategies. The goal of this trial is to determine whether substrate-guided catheter ablation is superior to activation-guided ablation in reducing atrial arrhythmia recurrence in patients with LAMRT. The SLICE-LAMRT trial is an investigator-initiated, prospective, multicenter, randomized (1:1) study conducted at 12 centers in Spain. Patients and clinical event adjudicators are blinded to treatment allocation. Patients with LAMRT and significant left atrial low-voltage substrate are randomized to either a conventional activation-guided ablation strategy, based on high-density mapping and entrainment pacing of clinical and inducible tachycardias, or a substrate-guided approach consisting of a predefined left atrial ablation line set. This study has been registered at ClinicalTrials.gov (NCT05842499). The primary endpoint is atrial tachyarrhythmia recurrence and time to first recurrence after a 3-month blanking period. Secondary endpoints include procedural performance, acute efficacy, major clinical outcomes (including hospitalizations and mortality), and echocardiographic parameters. Safety endpoints include procedure-related adverse events such as death, stroke, cardiac tamponade, vascular complications, and other major complications. The SLICE-LAMRT trial will provide the first randomized evidence comparing substrate-guided and activation-guided ablation strategies in LAMRT. By addressing a major unmet clinical need, this study may inform and refine ablation strategies for atypical atrial flutter and support a shift toward substrate-based approaches in complex atrial arrhythmias.
- Open Access
- 13 May 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (6)
Optimized workflow for pentaspline PFA and its impact on PVI durability: evidence from systematic remapping
Aims: Real-world series report substantial rates of pulmonary vein (PV) reconnection following index procedure with a pentaspline pulsed-field ablation (P-PFA) catheter. The contrast with initial durability data suggests this may be due to limitations in procedural workflow. Methods and results: We conducted a single-centre, prospective study including consecutive patients undergoing first-time P-PFA pulmonary vein isolation (PVI), subsequently scheduled for systematic invasive remapping ≥30 days after the index procedure. Workflow was progressively refined in three phases, aiming at ensuring adequate tissue contact and based on previous remapping findings. The primary endpoint was PVI durability, per vein and per patient. Of 118 enrolled patients, 94 (Phase 1:n = 30; Phase 2:n = 34; Phase 3:n = 30) underwent systematic remapping, where 13, 10, and 1 reconnected PVs were observed in Phases 1, 2, and 3, respectively. This resulted in per-vein durability of 89.8%, 92.9%, and 99.2% (P = 0.005) and per-patient durability of 60.0%, 76.5%, and 96.7% (P = 0.004). Mean total PFA applications increased from 36.8 ± 5.2 in Phase 1 to 52.1 ± 8.0 and 58.7 ± 15.1 in Phases 2 and 3, respectively (P < 0.001). Median procedure time rose from 43 (39–50) minutes in Phase 1 to 46 (42–56) minutes in Phase 2 and 69 (61–77) minutes in Phase 3 (P < 0.001), with significant parallel increases in LA dwell time (P < 0.001) across phases. No major or minor complications occurred during index or remapping procedures. Conclusion: Progressive workflow refinements for pentaspline P-PFA markedly improved PVI durability to nearly 100%, supporting the concept that PV reconnection is predominantly technique-dependent rather than intrinsic to catheter or waveform design.
- 13 May 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (6)
Open AccessOptimized workflow for pentaspline PFA and its impact on PVI durability: evidence from systematic remapping
Aims: Real-world series report substantial rates of pulmonary vein (PV) reconnection following index procedure with a pentaspline pulsed-field ablation (P-PFA) catheter. The contrast with initial durability data suggests this may be due to limitations in procedural workflow. Methods and results: We conducted a single-centre, prospective study including consecutive patients undergoing first-time P-PFA pulmonary vein isolation (PVI), subsequently scheduled for systematic invasive remapping ≥30 days after the index procedure. Workflow was progressively refined in three phases, aiming at ensuring adequate tissue contact and based on previous remapping findings. The primary endpoint was PVI durability, per vein and per patient. Of 118 enrolled patients, 94 (Phase 1:n = 30; Phase 2:n = 34; Phase 3:n = 30) underwent systematic remapping, where 13, 10, and 1 reconnected PVs were observed in Phases 1, 2, and 3, respectively. This resulted in per-vein durability of 89.8%, 92.9%, and 99.2% (P = 0.005) and per-patient durability of 60.0%, 76.5%, and 96.7% (P = 0.004). Mean total PFA applications increased from 36.8 ± 5.2 in Phase 1 to 52.1 ± 8.0 and 58.7 ± 15.1 in Phases 2 and 3, respectively (P < 0.001). Median procedure time rose from 43 (39–50) minutes in Phase 1 to 46 (42–56) minutes in Phase 2 and 69 (61–77) minutes in Phase 3 (P < 0.001), with significant parallel increases in LA dwell time (P < 0.001) across phases. No major or minor complications occurred during index or remapping procedures. Conclusion: Progressive workflow refinements for pentaspline P-PFA markedly improved PVI durability to nearly 100%, supporting the concept that PV reconnection is predominantly technique-dependent rather than intrinsic to catheter or waveform design.
- 29 March 2026
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 24 (4) , 385-392
Association between pre-existing heart failure and in-hospital outcomes and management in admissions with cardiogenic shock
Cardiogenic shock (CS) remains highly lethal despite advances in care. Preexisting heart failure (HF) is common in CS, but its effect on outcomes and management is unclear. Using the 2016-2019 National Inpatient Sample, we identified adults (≥18 years) hospitalized with CS and categorized them by presence of preexisting HF. The primary outcome was in-hospital mortality; secondary outcomes included pulmonary artery catheterization, mechanical circulatory support (MCS), renal replacement therapy, major bleeding, length of stay, and hospital charges. Multivariable logistic regression adjusted for demographics, comorbidities, and hospital characteristics. Of 640,660 CS admissions, 65.4% had HF. They were older, had more comorbidities, and were more often treated in large urban teaching hospitals. HF was associated with lower in-hospital mortality (adjusted odds ratio [aOR] 0.58; 95% CI 0.56-0.60; p < 0.001), but greater use of pulmonary artery catheterization (aOR 1.76), MCS (aOR 1.33), and renal replacement therapy (aOR 1.11). HF patients had longer stays (+1.6 days), higher charges (+$23,197), and less major bleeding (aOR 0.74; p < 0.001). Preexisting HF is associated with a distinct CS phenotype, including lower in-hospital mortality and higher resource utilization, highlighting the need for phenotype-specific strategies and refined risk models in CS management.
- 29 March 2026
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 24 (4) , 385-392
Association between pre-existing heart failure and in-hospital outcomes and management in admissions with cardiogenic shock
Cardiogenic shock (CS) remains highly lethal despite advances in care. Preexisting heart failure (HF) is common in CS, but its effect on outcomes and management is unclear. Using the 2016-2019 National Inpatient Sample, we identified adults (≥18 years) hospitalized with CS and categorized them by presence of preexisting HF. The primary outcome was in-hospital mortality; secondary outcomes included pulmonary artery catheterization, mechanical circulatory support (MCS), renal replacement therapy, major bleeding, length of stay, and hospital charges. Multivariable logistic regression adjusted for demographics, comorbidities, and hospital characteristics. Of 640,660 CS admissions, 65.4% had HF. They were older, had more comorbidities, and were more often treated in large urban teaching hospitals. HF was associated with lower in-hospital mortality (adjusted odds ratio [aOR] 0.58; 95% CI 0.56-0.60; p < 0.001), but greater use of pulmonary artery catheterization (aOR 1.76), MCS (aOR 1.33), and renal replacement therapy (aOR 1.11). HF patients had longer stays (+1.6 days), higher charges (+$23,197), and less major bleeding (aOR 0.74; p < 0.001). Preexisting HF is associated with a distinct CS phenotype, including lower in-hospital mortality and higher resource utilization, highlighting the need for phenotype-specific strategies and refined risk models in CS management.